EMA's concept paper defines biosimilar regulation problem areas
This article was originally published in Scrip
It looks as though forthcoming updates to guidelines on developing biosimilar medicines will reflect "current thinking and enhanced learning", if the European Medicines Agency's concept paper on proposed revisions are anything to go by, says Cecil Nick, a consultant for Parexel. The concept paper, put out for consultation on 3 October 2011, address issues including clinical equivalence studies requirements on immunogenicity.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.